Brief: ADC Therapeutics Doses First Patient In Phase 1 Clinical Trial Of ADCT-901 In Advanced Solid Tumors
27/09/2021 12:50
Sept 27 (Reuters) - ADC Therapeutics SA ADCT.N :
* ADC THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1 CLINICAL
TRIAL
OF ADCT-901 IN ADVANCED SOLID TUMORS
Source text for Eikon: ID:nBw5TZGjFa
Further company coverage: ADCT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adc Therapeutics
See all newsBrief: Adc Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics SA reports results for the quarter ended June 30 - Earnings Summary
ADC Therapeutics Q2 loss narrows; cuts 17% workforce
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview